bioRxivCell Biology
A novel iPSC model reveals selective vulnerability of neurons in Multiple Sulfatase Deficiency
V. Pham, L. S. Finoti, M. M. Cassidy, J. A. Maguire, A. L. Gagne, E. A. Waxman, D. L. French, K. King, P. Wongkittichotee, X. Hong, L. Schlotawa, B. L. Davidson, R. C. Ahrens-Nicklas
Abstract
Multiple sulfatase deficiency (MSD) is an ultra-rare, inherited lysosomal storage disease caused by mutations in the gene sulfatase modifying factor 1 (SUMF1). MSD is characterized by the functional deficiency of all sulfatase enzymes, leading to the storage of sulfated substrates including glycosaminoglycans (GAGs), sulfolipids, and steroid sulfates. Patients with MSD experience severe neurological impairment, hearing loss, organomegaly, corneal clouding, cardiac valve disease, dysostosis multiplex, contractures, and ichthyosis. Here, we generated a novel human model of MSD by reprogramming patient peripheral blood mononuclear cells to establish an MSD iPSC line (SUMF1 p.A279V). We also generated an isogenic control iPSC line by correcting the pathogenic variant with CRISPR/Cas9 gene editing. We successfully differentiated these iPSC lines into neural progenitor cells (NPCs) and NGN2-induced neurons (NGN2-iN) to model the neuropathology of MSD. Mature neuronal cells exhibited decreased SUMF1 gene expression, increased lysosomal stress, impaired neurite outgrowth and maturation, reduced sulfatase activities, and GAG accumulation. Interestingly, MSD iPSCs and NPCs did not exhibit as severe of phenotypes, suggesting that as neurons differentiate and mature, they become more vulnerable to loss of SUMF1. In summary, we demonstrate that this human iPSC-derived neuronal model recapitulates the cellular and biochemical features of MSD. These cell models can be used as tools to further elucidate the mechanisms of MSD pathology and for the development of therapeutics.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hematopoietic stem cell gene therapy improves outcomes in a clinically relevant mousemodel of Multiple Sulfatase Deficiency
Vi Pham, Lucas Tricoli, … Rebecca C. Ahrens‐Nicklas·Molecular TherapyPeer-reviewed·Aug 22, 2024
- MLC1 alteration in iPSCs give rise to disease-like cellular vacuolation phenotype in the astrocyte lineage
Saumya Sharma, Vishal Bharti, … Debojyoti Chakraborty·Orphanet Journal of Rare DiseasesPeer-reviewed·Mar 26, 2026
- Secondary deficiency of neuraminidase 1 contributes to CNS pathology in neurological mucopolysaccharidoses via hypersialylation of brain glycoproteins
TianMeng Xu, Rachel Heon‐Roberts, … Alexey V. Pshezhetsky·Journal of Clinical InvestigationPeer-reviewed·Jun 17, 2025
- Human iPSC-based neurodevelopmental models of globoid cell leukodystrophy uncover patient- and cell type-specific disease phenotypes
Elisabeth Mangiameli, Anna Cecchele, … Angela Gritti·Stem Cell ReportsPeer-reviewed·May 13, 2021
- Patient-Specific Midbrain Organoids with CRISPR Correction Recapitulate Neuronopathic Gaucher Disease Phenotypes and Enable Evaluation of Novel Therapies
Yi Lin, Benjamin Liou, … Ying Sun·bioRxiv·Nov 6, 2025
- An isogenic human iPSC model unravels neurodevelopmental abnormalities in SMA
Tobias Graß, Ines Rosignol, … Natalia Rodríguez‐Muela·bioRxiv·Jan 2, 2023